Buchumschlag

Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity

Background Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. However, residual disease can be detected in the majority of patients treated with imatinib. Compensatory activation of MAP kinases (MAPK1/2) in response to BCR-ABL-inhibitors has...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Härtel, Nicolai (VerfasserIn) , Hanfstein, Benjamin (VerfasserIn) , Müller, Martin Christian (VerfasserIn) , Erben, Philipp (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Journal of cancer research and clinical oncology
Year: 2011, Jahrgang: 138, Heft: 2, Pages: 203-212
ISSN:1432-1335
DOI:10.1007/s00432-011-1086-x
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s00432-011-1086-x
Verlag, Volltext: http://link.springer.com/10.1007/s00432-011-1086-x
Volltext
Verfasserangaben:Nicolai Härtel, Thomas Klag, Benjamin Hanfstein, Martin C. Mueller, Thomas Schenk, Philipp Erben, Andreas Hochhaus, Paul La Rosée
Beschreibung
Zusammenfassung:Background Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. However, residual disease can be detected in the majority of patients treated with imatinib. Compensatory activation of MAP kinases (MAPK1/2) in response to BCR-ABL-inhibitors has been reported as a potential cytokine-dependent resistance mechanism leading to the rescue of leukemic progenitor cells.
Beschreibung:Published online: 17 November 2011
Gesehen am 24.04.2018
Beschreibung:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-011-1086-x

Ähnliche Einträge